FDA approves new nasal spray for migraines

4
CBS News Videos

The Food and Drug Administration has approved a new nasal spray from Pfizer to treat migraines. Zavzpret is expected to be available in July.

Recommended Stories

  • Tranq making ‘deadliest drug threat’ in US ‘even deadlier,’ DEA warns

    The DEA says it has seized xylazine and fentanyl mixtures in all but two U.S. states.

  • 2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market

    Rewards that the next bull market will bring are being built right now by farsighted investors who can find opportunities among today's discounted stocks. While there's no telling exactly when a bull market will develop, planting the seeds of success by buying some shares of cheap yet high-quality companies out there right now is a good move. With that in mind, here are two businesses you're probably acquainted with that are priced for a no-brainer purchase -- and have a good shot at flourishing in the next bull market and beyond.

  • Beat the Dow Jones With This Unstoppable Dividend Stock

    The Dow Jones Industrial Average consists of 30 such businesses. A $10,000 investment made 10 years ago, with dividends reinvested along the way, would now be worth $76,000. Unsurprisingly, the company's status as a leading pharmaceutical company is supported by an exceptionally strong portfolio of products.

  • What's the Difference Between Ozempic, Wegovy, and Mounjaro?

    Physicians may prescribe type 2 diabetes drugs to lower blood sugar levels and promote weight loss in patients who meet specific criteria. While using type 2 diabetes drugs off-label for weight loss can be extremely effective, they are generally not recommended for people who are not overweight or living with obesity. Ozempic, Wegovy, and Mounjaro are all drugs that can be used to treat type 2 diabetes.

  • 4 Biotech Stocks to Consider for Your Portfolio in 2023

    New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

  • Karuna’s stock is up after schizophrenia drugs meets primary endpoint in clinical trial

    MARKET PULSE Shares of Karuna Therapeutics Inc. (KRTX) rallied about 14% in premarket trading on Monday after the company said its experimental treatment for adults with schizophrenia met the primary endpoint in a Phase 3 clinical trial.

  • Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

    Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategi

  • Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process

    The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood pressure, which are characteristics of the body that can be measured. The FDA will support using biomarkers as substitutes for other biological indicators in gene-therapy clinical trials to help clinch "accelerated approval," Reuters reported citing the agency's official Peter Marks. FDA grants acceler

  • Abortion pill access threatened in Nevada amid legal uncertainty

    Drug distributor AmerisourceBergen, the sole supplier of the pills to all pharmacies, is accused of taking an approach that could limit access.

  • Why Shares of Roivant Sciences Were Down Tuesday

    After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.

  • Narcan May Soon Be Available Over The Counter. Here's How To Use It.

    People may be able to purchase the treatment at their pharmacy in the coming months — a change experts are celebrating.

  • Roche teams up with Lilly to validate Alzheimer's blood test

    Roche and Eli Lilly and Co are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai and Biogen are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters.

  • Is Roche a Buy Now?

    Swiss healthcare company Roche Holding (OTC: RHHBY) doesn't trade on the NYSE or NASDAQ, so the company is sometimes overlooked considering its size, scope and consistent revenue growth. Roche, with its roughly 140,000 employees, has increased revenue by 36% over the past 10 years and annual earnings per share (EPS) by 27% in that period. There are two likely reasons for the decline of Roche's shares.

  • Judge in Fox News, Dominion Case Says Network’s Legal Woes Mostly the Fault of One ‘Problem’ Host

    "This seems to be a Lou Dobbs problem," Judge Eric Davis said

  • When My Dad Got Cancer, I Kept Asking, 'Why Him?' His 3-Word Response Floored Me.

    "It was 10 months into his treatment when I finally broke in front of him, and he revealed the surprising yet profound truth he was using to guide his way through his diagnosis."

  • Tucker Carlson Laughed Out Of The Room With Eyebrow-Raising New Trump Defense

    "This is what's known as telling on yourself," one Twitter user commented.

  • Fox News producer alleges Tucker Carlson's team plastered photos around the office of Nancy Pelosi in a bathing suit 'revealing her cleavage'

    A Fox News producer accused the conservative media giant of rampant sexism and discrimination in the workplace in a lawsuit filed on Monday.

  • Man diagnosed with stage 4 colon cancer at 29 shares symptoms: 'It hit me pretty hard'

    More young people are getting colon cancer. A man diagnosed at age 29 shares symptoms as part of this trend — pelvic pain, blood in stool, not being able to sit

  • Chris Christie Nails Donald Trump's Strategy As The Law Closes In

    The former Trump confidant broke down the former president's behavior ahead of a possible indictment.

  • Vladimir Putin’s health may be disintegrating and it should terrify us all

    Images of Putin gripping his chair and squirming next to President Xi in Moscow have again fuelled speculation about his health. He was filmed limping during a visit to Crimea a few days ago and during a February meeting with Belarus leader Alexander Lukashenko his leg was shaking uncontrollably. Since Putin invaded Ukraine last year, rumours of his physical well-being have been rife, with a range of theories from cancer to Parkinson’s.